Heart rate reduction in heart failure: Ivabradine or beta blockers?

Heart Failure Reviews

Volumn 18, Issue 4, 2013, Pages 517-528

  Guglin, Maya ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Beta blockers; Heart failure; Heart rate; Ivabradine; Vagal stimulation

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IVABRADINE; LISINOPRIL; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO;

ANGINA PECTORIS; BRADYCARDIA; CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HEART DILATATION; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEART TRANSPLANTATION; HEART VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; REVIEW; SINUS RHYTHM; SINUS TACHYCARDIA; SYMPTOM; SYSTOLIC DYSFUNCTION; TACHYCARDIA; VAGUS NERVE STIMULATION;

ADRENERGIC BETA-ANTAGONISTS; BENZAZEPINES; CARDIOTONIC AGENTS; EUROPE; EVIDENCE-BASED MEDICINE; HEART FAILURE; HEART RATE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84879094675     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-012-9347-6     Document Type: Review

References (76)

1. Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159(6):585-592
2. Jouven X, Empana JP, Escolano S, Buyck JF, Tafflet M, Desnos M et al (2009) Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 103(2):279-283. doi: 10.1016/j.amjcard.2008.08.071
3. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113(6):1489-1494
4. Cucherat M (2007) Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 28(24):3012-3019. doi: 10.1093/eurheartj/ehm489
5. Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE et al (1986) Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 57(8):563-570
6. Thackray SD, Ghosh JM, Wright GA, Witte KK, Nikitin NP, Kaye GC et al (2006) The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 152(4):713 e719-713. doi: 10.1016/j.ahj.2006.07.007
7. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM (1997) Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12):2660-2667
8. Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryden L (2003) Mode of death in heart failure: findings from the ATLAS trial. Heart 89(1):42-48
9. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV et al (1997) Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina. J Am Coll Cardiol 29(6):1199-1205
10. Kapoor JR, Heidenreich PA (2010) Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail 16(10):806-811. doi: 10.1016/j.cardfail.2010.04.013
11. Thollon C, Bidouard JP, Cambarrat C, Lesage L, Reure H, Delescluse I et al (1997) Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 339(1):43-51
12. DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64(16):1757-1765
13. Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF et al (2006) Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 61(2):127-137. doi: 10.1111/j.1365-2125.2005. 02544.x
14. Manz M, Reuter M, Lauck G, Omran H, Jung W (2003) A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100(3):149-155. doi: 10.1159/000073933
15. Camm AJ, Lau CP (2003) Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4(2):83-89
16. Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I et al (2011) Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol 107(6):805-811. doi: 10.1016/j.amjcard.2010.10.065
17. Borer JS, Fox K, Jaillon P, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107(6):817-823
18. Tardif JC, Ponikowski P, Kahan T (2009) Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30(5):540-548. doi: 10.1093/eurheartj/ehn571
19. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C et al (2008) Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 10(6):550-555. doi: 10.1016/j.ejheart.2008.04.005
20. Ceconi C, Cargnoni A, Francolini G, Parinello G, Ferrari R (2009) Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res 84(1):72-82. doi: 10.1093/cvr/cvp158
21. Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, Cerbai E et al (2011) Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 300(1):H366-H373. doi: 10.1152/ajpheart.01117.2009
22. Christensen LP, Zhang RL, Zheng W, Campanelli JJ, Dedkov EI, Weiss RM et al (2009) Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. Am J Physiol Heart Circ Physiol 297(1):H322-H330. doi: 10.1152/ajpheart.01337.2008
23. Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E et al (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117(3):234-242. doi: 10.1159/000322905
24. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F et al (2004) Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109(13):1674-1679. doi: 10.1161/01.cir.0000118464.48959.1c
25. Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F et al (2012) Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 59(3):260-267. doi: 10.1097/FJC.0b013e31823e5e01
26. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C (2009) Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 296(2):H435-H441. doi: 10.1152/ajpheart.00591.2008
27. Volterrani M, Cice G, Caminiti G, Vitale C, D'Isa S, Perrone Filardi P et al (2011) Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 151(2):218-224. doi: 10.1016/j.ijcard.2011.06.098
28. Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32(19):2395-2404. doi: 10.1093/eurheartj/ehr343
29. Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S et al (2010) Impact of "off-label" use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther 15(4):349-355. doi: 10.1177/1074248410370326
30. Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807-816. doi: 10.1016/s0140-6736(08)61170-8
31. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 30(19):2337-2345. doi: 10.1093/eurheartj/ehp358
32. Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P et al (2011) Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol 146(3):408-414. doi: 10.1016/j.ijcard.2010.10.125
33. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875-885. doi: 10.1016/s0140-6736(10) 61198-1
34. Tardif JC, O'Meara E, Komajda M, Bohm M, Borer JS, Ford I et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32(20):2507-2515. doi: 10.1093/eurheartj/ehr311
35. Lage-Galle E, Romero-Rodriguez N, Nevado-Portero J, Guisado-Rasco A, Sobrino-Marquez M, Machuca MG et al (2010) Safety and effectiveness of ivabradine after cardiac transplantation. Transplant Proc 42(8):3191-3192. doi: 10.1016/j.transproceed.2010.05.125
36. Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L et al (2009) Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 88(6):835-841. doi: 10.1097/TP.0b013e3181b4e0f5
37. Zhang R, Haverich A, Struber M, Simon A, Pichlmaier M, Bara C (2008) Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol 97(11):811-819. doi: 10.1007/s00392-008-0690-5
38. Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A et al (2007) Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine. Transplantation 84(8):988-996. doi: 10.1097/01.tp.0000285265.86954.80
39. Zhang R, Bobylev D, Stiefel P, Haverich A, Bara C (2012) Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study. Clin Res Cardiol. doi: 10.1007/s00392-012-0436-2
40. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. doi: 10.1093/eurheartj/ehs104
41. Cullington D, Goode KM, Cleland JG, Clark AL (2011) Limited role for ivabradine in the treatment of chronic heart failure. Heart 97(23):1961-1966. doi: 10.1136/heartjnl-2011-300041
42. Castagno D, Petrie MC, Claggett B, McMurray J (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33(9):1137-1141. doi: 10.1093/eurheartj/ehs004
43. DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320(11):677-683. doi: 10.1056/nejm198903163201101
44. Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U et al (2005) What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 45(2):252-259. doi: 10.1016/j.jacc.2004.10.032
45. Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M et al (2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26(21):2259-2268. doi: 10.1093/eurheartj/ehi386
46. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M et al (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103(10):1428-1433
47. Gelbrich G, Edelmann F, Inkrot S, Lainscak M, Apostolovic S, Neskovic AN et al (2012) Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. Int J Cardiol 155(1):160-166. doi: 10.1016/j.ijcard.2011.11.018
48. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784-794
49. Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101(6):865-869. doi: 10.1016/j.amjcard.2007.11.023
50. Huang RL, Listerman J, Goring J, Giesberg C, Nading MA, Butler J (2006) Beta-blocker therapy for heart failure: should the therapeutic target be dose or heart rate reduction? Congest Heart Fail 12(4):206-210 (quiz 211-202)
51. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (systolic heart failure treatment with the I(f) inhibitor ivabradine trial) Study. J Am Coll Cardiol. doi: 10.1016/j.jacc.2012.01.020
52. Cullington D, Goode KM, Clark AL, Cleland JG (2012) Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. doi: 10.1093/eurjhf/hfs060
53. Nagatsu M, Spinale FG, Koide M, Tagawa H, DeFreitas G, Cooper G et al (2000) Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation 101(6):653-659
54. Guth BD, Heusch G, Seitelberger R, Ross J Jr (1987) Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 60(5):738-746
55. Simonsen S, Ihlen H, Kjekshus JK (1983) Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. Acta Med Scand 213(5):393-398
56. Ulu N, Henning RH, Goris M, Schoemaker RG, van Gilst WH (2009) Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure. J Cardiovasc Pharmacol 53(1):9-17. doi: 10.1097/FJC.0b013e318193dfce
57. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26(23):2529-2536. doi: 10.1093/eurheartj/ehi586
58. Parakh N, Chaturvedi V, Kurian S, Tyagi S (2012) Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail 18(4):282-288. doi: 10.1016/j.cardfail.2012.01.001
59. Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF et al (2002) Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 282(2):H672-H679. doi: 10.1152/ajpheart.00547.2001
60. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R (2011) Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 25(6):531-537. doi: 10.1007/s10557-011-6327-3
61. Becher PM, Lindner D, Miteva K, Savvatis K, Zietsch C, Schmack B et al (2012) Role of heart rate reduction in the prevention of experimental heart failure: comparison between if-channel blockade and beta-receptor blockade. Hypertension 59(5):949-957. doi: 10.1161/hypertensionaha.111.183913
62. Riesen SC, Schober KE, Cervenec RM, Bonagura JD (2011) Comparison of the effects of ivabradine and atenolol on heart rate and echocardiographic variables of left heart function in healthy cats. J Vet Intern Med 25(3):469-476. doi: 10.1111/j.1939-1676.2011.0705.x
63. Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G et al (2009) Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail 15(10):856-863. doi: 10.1016/j.cardfail.2009.05.013
64. Maczewski M, Mackiewicz U (2008) Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res 79(1):42-51. doi: 10.1093/cvr/cvn057
65. Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P (2012) Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study. Am J Cardiovasc Drugs 12(3):179-188. doi: 10.2165/11597400-000000000-00000
66. Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, Starling RC et al (2012) Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: iNOVATE-HF. Am Heart J 163(6):954-962 e951. doi: 10.1016/j.ahj.2012.03.021
67. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109(1):120-124. doi: 10.1161/01.cir.0000105721. 71640.da
68. Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA et al (2011) Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 4(1):65-70. doi: 10.1161/circheartfailure.110.955013
69. De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M et al (2011) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 32(7):847-855. doi: 10.1093/eurheartj/ehq391
70. Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT (2012) Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur J Heart Fail. doi: 10.1093/eurjhf/hfs104
71. Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA et al (1997) Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 96(7):2197-2205
72. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372(9641):817-821. doi: 10.1016/s0140- 6736(08)61171-x
73. Ahmadi-Kashani M, Kessler DJ, Day J, Bunch TJ, Stolen KQ, Brown S et al (2009) Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation 120(21):2040-2045. doi: 10.1161/circulationaha.108. 847608
74. Chonchol M, Goldenberg I, Moss AJ, McNitt S, Cheung AK (2007) Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol 27(1):7-14. doi: 10.1159/000098431
75. Opasich C, Rapezzi C, Lucci D, Gorini M, Pozzar F, Zanelli E et al (2001) Precipitating factors and decision-making processes of short-term worsening heart failure despite "optimal" treatment (from the IN-CHF Registry). Am J Cardiol 88(4):382-387
76. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB et al (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in heart failure: assessment of reduction in mortality and morbidity) program. J Am Coll Cardiol 59(20):1785-1795. doi: 10.1016/j.jacc.2011.12.044